CMPS Stock Clocks 25% Gains In August Ahead Of Application Filing For Drug, FDA Hearing On Psychedelics

• The company expects to finish the full submission in the fourth quarter of this year.
• An earlier FDA decision to grant a special priority voucher for COMP360 could significantly shorten the final review period. 
• Broader policy shifts and big pharma interest in psychedelic therapies have added to the positive mood around CMPS.

Shares of Compass Pathways (CMPS) rose more than 6% on Monday amid optimism about its lead program application filing timeline and a more supportive backdrop for new therapies in the field of psychedelics.

The stock has gained 25% in August, on track for its best month since May, when it clocked 44% gains. 

Upcoming Catalysts On The Horizon

The most closely watched next step for Compass is the completion of its application to the U.S. Food and Drug Administration for COMP360, its synthetic psilocybin treatment aimed at people with depression that has not responded to other options. Portions of the filing are already under review, and the company expects to finish the full submission in the fourth quarter of this year. If approved, a launch could follow in the first half of 2027.

An earlier FDA decision to grant a special priority voucher for COMP360 could significantly shorten the final review period, potentially to just one or two months after the complete package is in. 

Two large late-stage studies showed the therapy can produce benefits that begin quickly and last for months. Compass is also advancing a late-stage study in post-traumatic stress disorder and has begun building the teams and partnerships needed for a commercial rollout.

CMPS Q2 Earnings

In early August, Compass reported its second-quarter results. The company posted a larger loss than in prior periods as it ramped up preparations for a potential product launch. At the same time, it held a solid cash position of $433 million at the end of June, sufficient to support operations well beyond a potential market entry and into 2028.

Broader policy shifts have added to the positive mood around CMPS. Earlier this year, an executive order directed federal agencies to speed research and access to promising treatments for serious mental health conditions. The FDA followed with steps that include priority vouchers for certain psychedelic programs, updated guidance for clinical studies, and plans for further public discussion of how these therapies might be used. The FDA is also slated to hold a psychedelic hearing next month to gather public feedback and perspectives on the potential future therapeutic use of drug products that contain a psychedelic substance. 

Mainstream pharmaceutical companies have also stepped up their interest in psychedelic therapies this year with two notable deals. In March, Otsuka Pharmaceutical agreed to acquire Transcend Therapeutics for up to $1.225 billion, gaining its methylone candidate for post-traumatic stress disorder. Then in July, Eli Lilly announced it would buy AtaiBeckley for up to $3.8 billion, securing a late-stage nasal-spray psychedelic aimed at treatment-resistant depression, and underscoring growing confidence in the field.

How Did CMPS Retail Traders React?

On Stocktwits, retail sentiment around CMPS stock improved from ‘bearish’ to ‘bullish’ over the past 24 hours, while message volume remained at ‘normal’ levels. 

A Stocktwits user noted that the stock has multiple catalysts coming and expressed optimism about it going up. 

Another user opined that the stock should have steady stock action in light of its high institutional ownership. 

One user voiced anticipation of the stock rallying ahead of the final application submission.

Meanwhile, another user expressed anticipation for the FDA psychedelics hearing scheduled for September, providing a push-up for the stock. 

CMPS stock has more than doubled year-to-date. 

For updates and corrections, email newsroom[at]stocktwits[dot]com.<